Amylin Pharmaceuticals, Inc.

Satiogen Pharmaceuticals, Inc.

Shire Human Genetic Therapies, Inc.

Astrazeneca Pharmaceuticals LP

Lumena Pharmaceutials LLC

Lumena Pharmaceuticals LLC

Bronislava Gedulin

Andrew A Young

Howard E Greene

Michael Grey

Niall O'Donnell

Sunil Bhavsar

Kathryn Susan Prickett

David Geoffrey Parkes

Nigel Robert Arnold Beeley

Krystyna Tatarkiewicz

Denis Roy

Gareth Wyn Beynon

Niall O'donnell

Andrew Young

James Paterniti

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease

Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions

Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Bile acid recycling inhibitors for treatment of obesity and diabetes

Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.

Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof

The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.

Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis

Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Exendin and exendin agonists for eating disorders

Growing community of inventors

Del Mar, CA, United States of America

Bronislava Gedulin